MWNA
DNTH icon

Marshall Wace North America’s Dianthus Therapeutics DNTH Stock Holding History

Marshall Wace North America’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-7,075
Closed -$850K – 1266
2020
Q2 		$850K Sell
7,075
-3,086
-30% -$435K 0.01% 798
2020
Q1 		$1.02M Buy
10,161
+2,155
+27% +$399K 0.01% 605
2019
Q4 		$1.94M Buy
+8,006
New +$1.5M 0.01% 584
2018
Q3 		– Sell
-625
Closed -$135K – 1017
2018
Q2 		$135K Buy
+625
New +$141K ﹤0.01% 1304

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Marshall Wace North America's DNTH Position: Q3 2020 in Review

Marshall Wace North America sold out of Dianthus Therapeutics (DNTH) in Q3 2020, closing a stake of 7,075 shares — an estimated $850K sold.

Marshall Wace North America first reported a position in DNTH in Q2 2018 and held it in 4 quarters. The position peaked at $1.94M in Q4 2019. 94 funds tracked by Wall St. Rank hold DNTH as of Q3 2020.

  • Marshall Wace North America reported no remaining Dianthus Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Marshall Wace North America sold 7,075 Dianthus Therapeutics shares in Q3 2020, an estimated $850K.
  • Marshall Wace North America first reported a position in Dianthus Therapeutics in Q2 2018 and held it in 4 quarters.
  • Marshall Wace North America's Dianthus Therapeutics position peaked at $1.94M in Q4 2019.
  • 94 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2020.

Based on Marshall Wace North America's 13F filing for Q3 2020, filed 16 Nov 2020.